Bioengineering, clinical and therapeutical trends in transcatheter aortic valve implantation

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1851-1852

  Vavuranakis, Manolis ^a   Vrachatis, Dimitrios A ^a   Tousoulis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR;

ANTICOAGULANT THERAPY; AORTA STENOSIS; ATRIAL FIBRILLATION; BACTERIAL ENDOCARDITIS; BIOENGINEERING; BRAIN INFARCTION; CLINICAL PRACTICE; EDITORIAL; GENETIC VARIATION; HIGH RISK PATIENT; HUMAN; KIDNEY INJURY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL ANESTHESIA; SURGICAL MORTALITY; SURGICAL RISK; THROMBOSIS; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT RESPONSE; VALVULAR HEART DISEASE; AORTIC VALVE STENOSIS; TRENDS;

AORTIC VALVE STENOSIS; BIOENGINEERING; HUMANS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964240568     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822999160222120132     Document Type: Editorial

References (14)

1. Karamanou M, Tsoucalas G, Gialafos E, Vrachatis DA, Androutsos G, Poulakou-Rebelakou E. Jean-Baptiste de Sénac’s (1693-1770) important work on cardiology and valvular disorders. Curr Pharm Des 2016; 22(13): 1853-6.
2. Tsoucalas G, Chevallier J, Karamanou M, Papaioannou T, Sgantzos M, Androutsos G. Historical hallmarks of anticoagulation and antiplatelet agents. Curr Pharm Des 2016; 22(13): 1857-61.
3. Lilly SM, Abraham WT. Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends. Curr Pharm Des 2016; 22(13): 1862-7.
4. Maas EHA, Pieters BMA, Van de Velde M, Rex S. General or local anesthesia for TAVI? A systematic review of the literature and meta-analysis. Curr Pharm Des 2016; 22(13): 1868-78.
5. Naderi AS, Frerker C, Kuck K-H, Ghanem A. Mechanisms and prevention of TAVI-related cerebrovascular events. Curr Pharm Des 2016; 22(13): 1879-87.
6. Magkoutis NA, Fradi S, Azmoun A, Ramadan R, Ouanes SB, Vavuranakis M, Vrachatis DA, Papaioannou TG, Tousoulis D, Ghostine S. Antiplatelet therapy in TAVI. Current clinical practice and recommendations. Curr Pharm Des 2016; 22(13): 1888-95.
7. Vavuranakis M, Kolokathis A-M, Vrachatis DA, Kalogeras K, Magkoutis NA, Fradi S, Ghostine S, Karamanou M, Tousoulis D. Atrial Fibrillation during or after TAVI: Incidence, implications and therapeutical considerations. Curr Pharm Des 2016; 22(13): 1896-903.
8. Puri R, Altisent mA-J, Campelo-Parada F, el Trigo M, Regueiro A, Rodés-Cabau J. Balancing the Risks of Thrombosis and Bleeding Following Transcatheter Aortic Valve Implantation: Current State-of-Evidence. Curr Pharm Des 2016; 22(13): 1904-10.
9. Mastoris I, Dangas GD. Bivalirudin or Heparin treatment during Transcatheter valve interventions: Where are we now? Curr Pharm Des 2016; 22(13): 1911-7.
10. Dobesh PP, Varnado S, Dolyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. Curr Pharm Des 2016; 22(13): 1918-32.
11. Storelli F, Daali Y, Desmeules Y, Reny J-L, Fontana P. Pharmacogenomics of Oral Antithrombotic Drugs. Curr Pharm Des 2016; 22(13): 1933-49.
12. Kampaktsis PN, Feldman DN, Charitakis K. Strategies to Avoid TAVI-related Acute Kidney Injury. Curr Pharm Des 2016; 22(13): 1950-58.
13. Ben-Shoshan J, Amit S, Finkelstein A. Transcatheter aortic valve implantation infective endocarditis: Current data and implications on prophylaxis and management. Curr Pharm Des 2016; 22(13): 1959-64.
14. Cao C, Liou KP, Pathan FK, Virk S, McMonnies R, Wolfenden H, Indraratna P. A Systematic Review and Meta-analysis of Clinical and Costeffective Outcomes of Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement. Curr Pharm Des 2016; 22(13): 1965-77.